Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M48,634Revenue $M6,022Net Margin (%)58.6Z-Score7.9
Enterprise Value $M143,191EPS $17.3Operating Margin %30.4F-Score7
P/E(ttm))14.8Cash Flow Per Share $7.1Pre-tax Margin (%)57.4Higher ROA y-yY
Price/Book5.310-y EBITDA Growth Rate %0Quick Ratio1.5Cash flow > EarningsY
Price/Sales8.65-y EBITDA Growth Rate %27.7Current Ratio1.7Lower Leverage y-yY
Price/Cash Flow12.9y-y EBITDA Growth Rate %78.6ROA % (ttm)27.7Higher Current Ratio y-yN
Dividend Yield %0.3Insider Buy (3m)0ROE % (ttm)50.2Less Shares Outstanding y-yY
Payout Ratio %4.0Shares Outstanding M200ROI % (ttm)11.5Gross Margin Increase y-yN

Gurus Latest Trades with SHPG

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
SHPGMario Gabelli 2015-03-31 Sold Out -0.018%$205.66 - $253.64
($229.81)
$ 243.906%Sold Out0
SHPGKen Fisher 2015-03-31 Add$205.66 - $253.64
($229.81)
$ 243.906%Add 1.35%14,791
SHPGLeon Cooperman 2014-12-31 Buy 1.7%$170.49 - $262.71
($211.39)
$ 243.9013%New holding473,237
SHPGJohn Paulson 2014-12-31 Reduce-0.77%$170.49 - $262.71
($211.41)
$ 243.9013%Reduce -7.93%8,328,304
SHPGDavid Tepper 2014-12-31 Sold Out -0.71%$170.49 - $262.71
($211.58)
$ 243.9013%Sold Out0
SHPGJean-Marie Eveillard 2014-12-31 Add0.04%$170.49 - $262.71
($211.58)
$ 243.9013%Add 453.24%82,986
SHPGMario Gabelli 2014-12-31 Reduce-0.03%$170.49 - $262.71
($211.58)
$ 243.9013%Reduce -57.13%16,225
SHPGKen Fisher 2014-12-31 Add0.01%$170.49 - $262.71
($211.58)
$ 243.9013%Add 416.24%14,594
SHPGJohn Paulson 2014-09-30 Add6.09%$231.98 - $262.64
($248.14)
$ 243.90-2%Add 168.70%9,046,000
SHPGDavid Tepper 2014-09-30 Buy 0.71%$231.98 - $262.64
($248.14)
$ 243.90-2%New holding185,944
SHPGMario Gabelli 2014-09-30 Buy 0.05%$231.98 - $262.64
($248.14)
$ 243.90-2%New holding37,850
SHPGJean-Marie Eveillard 2014-09-30 Buy 0.01%$231.98 - $262.64
($248.14)
$ 243.90-2%New holding15,000
SHPGKen Fisher 2014-09-30 Reduce$231.98 - $262.64
($248.14)
$ 243.90-2%Reduce -39.56%2,827
SHPGJohn Paulson 2014-06-30 Add0.84%$142.83 - $234.98
($172.9)
$ 243.9029%Add 33.07%3,366,539
SHPGKen Fisher 2014-06-30 Add$142.83 - $234.98
($172.9)
$ 243.9029%Add 91.13%4,677
SHPGJohn Paulson 2013-12-31 Reduce-0.24%$113.87 - $140.87
($131.38)
$ 243.9046%Reduce -11.03%2,529,854
SHPGJohn Paulson 2013-06-30 Add0.98%$86.59 - $99.85
($93.74)
$ 243.9062%Add 107.43%2,843,500
SHPGMario Gabelli 2013-03-31 Sold Out -0.003%$89.83 - $101.63
($95.88)
$ 243.9061%Sold Out0
SHPGJohn Paulson 2012-09-30 Buy 0.99%$84.65 - $95.05
($89.88)
$ 243.9063%New holding1,370,800
SHPGKen Fisher 2012-09-30 Reduce-0.14%$84.65 - $95.05
($89.88)
$ 243.9063%Reduce -99.55%2,480
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

SHPG is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


SHPG: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Press Releases about SHPG :

    Quarterly/Annual Reports about SHPG:

    News about SHPG:

    Articles On GuruFocus.com
    Top Stock Picks Among Companies That Recently Increased Dividends Mar 09 2015 
    AbbVie To Acquire Biopharmaceutical Firm Pharmacyclics Mar 06 2015 
    Valeant Pharmaceuticals Finally Zeros In On Salix Pharmaceuticals Feb 24 2015 
    Three Pharma Majors In The Run To Acquire Salix Feb 16 2015 
    Pioneer Investments Purchases Time Warner Cable, Kohl's in Q4 Feb 10 2015 
    AbbVie’s Q4 Reflects Its Tremendous Growth Potential Going Forward Feb 04 2015 
    Shire Set To Acquire NPS Pharmaceuticals for $5.2 Billion Jan 15 2015 
    Invesco European Growth Fund Comments on Shire PLC Dec 30 2014 
    Invesco European Growth Fund Q4 2014 Management’s Discussion Dec 30 2014 
    Activist Investor Dan Loeb Stays Active in Third Quarter Dec 08 2014 


    More From Other Websites
    Novartis (NVS) Beats on Earnings in Q1, View Reiterated - Analyst Blog Apr 24 2015
    Why Are Shire PLC And Hikma Pharmaceuticals Plc Wiping The Floor With GlaxoSmithKline plc? Apr 24 2015
    Shire Gets Dropped from AQR Capital’s Portfolio Apr 23 2015
    AbbVie raises outlook as Humira again delivers earnings beat Apr 23 2015
    AbbVie raises outlook as Humira again delivers earnings beat Apr 23 2015
    Roche Beats on Q1 Sales driven by Oncology & Immunology - Analyst Blog Apr 23 2015
    AbbVie raises guidance after 1Q sales beat Apr 23 2015
    AbbVie raises guidance after 1Q sales beat Apr 23 2015
    Abbott Labs (ABT) Beats on Q1 Earnings, View Reiterated - Analyst Blog Apr 22 2015
    Hedge fund manager targets patent for Biogen's blockbuster MS drug, Tecfidera Apr 22 2015
    3 Large-Cap Pharmaceutical Companies to Invest in Right Now Apr 22 2015
    Seattle Genetics' Adcetris Under Review for New Indication - Analyst Blog Apr 21 2015
    Merck KGaA-Pfizer Start First Cancer Registration Study - Analyst Blog Apr 21 2015
    Ampio Plunges as STRIDE Study on Ampion Fails - Analyst Blog Apr 21 2015
    SHIRE PLC Files SEC form 8-K, Financial Statements and Exhibits Apr 21 2015
    Shire to announce first quarter 2015 results Apr 21 2015
    Pharmacyclics Shares Fall As Kyle Bass Files Petition To Cancel Patent Apr 20 2015
    Should You Sell Petrofac Limited, Shire PLC And Standard Chartered PLC? Apr 20 2015
    Goldman's Monster Q1 Spurred By Megadeals, Volatility Apr 16 2015
    Maverick Capital Eliminates Its Position in AbbVie Apr 16 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK